酪氨酸激酶抑制剂联合抗PD-1抗体治疗不可切除晚期肝细胞癌的超声造影疗效评估
前瞻性队列纳入2022年1月至10月接受酪氨酸激酶抑制剂联合抗PD-1抗体治疗的不可切除肝细胞癌患者24例,比较超声造影与增强磁共振/CT评估靶肿瘤坏死程度及疗效。超声造影与增强磁共振/CT评估坏死程度无显著差异(44.5±36.2% vs 45.3±36.8%,p=0.862),mRECIST-超声造影与mRECIST-增强磁共振/CT一致性高(κ=0.812),而常规超声RECIST 1.1与mRECIST-超声造影一致性差(κ=0.233)。
要点
- 超声造影与增强磁共振/CT评估靶肿瘤坏死程度无显著差异,一致性高(κ=0.812)。
- 常规超声RECIST 1.1与mRECIST-超声造影区分有效者与无效者一致性差(κ=0.233)。
- 超声造影在评估联合靶向免疫治疗疗效方面优于基线常规超声。
核心结论
- 超声造影在定义酪氨酸激酶抑制剂联合抗PD-1抗体治疗疗效方面优于基线常规超声,与增强磁共振/CT相当。
研究设计与样本
- 前瞻性队列研究,纳入2022年1月至10月接受酪氨酸激酶抑制剂联合抗PD-1抗体治疗的不可切除肝细胞癌连续患者24例(男23例、女1例,平均年龄56.5±8.5岁,巴塞罗那临床肝癌C期占62.5%,肝内靶肿瘤29个),治疗前及随访时行常规超声和超声造影检查,以增强磁共振/CT为参照。
诊断标准与关键数值
- 靶肿瘤坏死程度:超声造影44.5±36.2% vs 增强磁共振/CT 45.3±36.8%,p=0.862;常规超声RECIST 1.1与mRECIST-超声造影区分有效者与无效者的κ系数=0.233;mRECIST-超声造影与mRECIST-增强磁共振/CT的κ系数=0.812。
临床应用与阅片要点
- 作者认为超声造影在评估酪氨酸激酶抑制剂联合抗PD-1抗体治疗疗效方面优于基线常规超声,与增强磁共振/CT相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of the work described here was to evaluate the role of contrast-enhanced ultrasound (CEUS) in response evaluation for unresectable advanced hepatocellular carcinoma (HCC) treated with tyrosine kinase inhibitors (TKIs) plus anti-programmed cell death protein-1 (PD-1) antibody therapy.
METHODS: A prospective cohort of consecutive patients with HCC who received combined TKI/anti-PD-1 antibody treatment for unresectable HCC between January 2022 and October 2022 was included in this study. The patients underwent unenhanced ultrasound (US) and CEUS examinations before treatment and at follow-up. Changes in the largest diameters of the target tumor on unenhanced US and the largest diameters of the enhancing target tumors on CEUS were evaluated. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 with unenhanced US and magnetic resonance imaging/computed tomography (MRI/CT) and modified RECIST (mRECIST) with CEUS and CEMRI/CT were used to assess treatment response.
RESULTS: A total of 24 HCC patients (23 men and 1 woman; mean age: 56.5 ± 8.5 y; Barcelona Clinic Liver Cancer stage C, 62.5%; 29 intrahepatic target tumors) were studied. Calculations of degree of necrosis in the target tumors revealed no significant differences between CEUS and CEMRI/CT (44.5 ± 36.2% vs. 45.3 ± 36.8%, p = 0.862). As for the differentiation of responders from non-responders, the agreement between RECIST version 1.1 of unenhanced US and mRECIST-CEUS was poor (κ coefficient = 0.233). Meanwhile, there was a high degree of concordance between mRECIST-CEUS and mRECIST-CEMRI/CT (κ coefficient = 0.812).
CONCLUSION: CEUS proved to be superior to baseline US and is comparable to CEMRI/CT in defining treatment outcome for combined TKI/anti-PD-1 antibody therapy.
引用
- Zhao CK, Guan X, Pu YY, et al. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy. Ultrasound Med Biol. 2023. PMID: 37852872. doi:10.1016/j.ultrasmedbio.2023.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。